Results 41 to 50 of about 76,979 (321)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

Human Vaccines & Immunotherapeutics, 2019
Background: Pneumococcal disease remains a public health priority in adults. Safety and immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) containing 13 serotypes included in 13-valent pneumococcal conjugate ...
Helen L Stacey, Jeffrey Rosen, James T Peterson, A. Williams-Diaz, Vanita Gakhar, T. Sterling, C. Acosta, Katrina M. Nolan, Jianing Li, Alison Pedley, Patrice Benner, Chitrananda Abeygunawardana, Michael Kosinski, William J. Smith, H. Pujar, L. Musey   +15 more
semanticscholar   +1 more source

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN

Педиатрическая фармакология, 2014
Compulsory use of the 7-valent pneumococcal conjugate vaccine in the framework of national pediatric immunization schedules of the developed countries resulted in significant decrease in the prevalence of the pneumococcal infections induced by the ...
M. V. Fedoseenko, D. A. Novikova, N. E. Tkachenko, M. I. Broeva, T. A. Grechukha, A. G. Gaivoronskaya, V. V. Chernikov   +6 more
doaj   +1 more source

Bayesian learning of COVID-19 Vaccine safety while incorporating Adverse Events ontology [PDF]

arXiv, 2022
While vaccines are crucial to end the COVID-19 pandemic, public confidence in vaccine safety has always been vulnerable. Many statistical methods have been applied to VAERS (Vaccine Adverse Event Reporting System) database to study the safety of COVID-19 vaccines. However, all these methods ignored the adverse event (AE) ontology.
arxiv  

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design

Clinical Infectious Diseases, 2018
Our study demonstrated real-world, direct effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia following introduction into a routine immunization program among adults aged ≥65 years, many of whom had
J. McLaughlin, Q. Jiang, R. Isturiz, H. Sings, D. Swerdlow, B. Gessner, R. Carrico, P. Peyrani, T. Wiemken, William A. Mattingly, J. Ramirez, L. Jodar   +11 more
semanticscholar   +1 more source

Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil. [PDF]

, 2017
BackgroundPneumococcal conjugate vaccines (PCVs) are being used worldwide. A key question is whether the impact of PCVs on pneumonia is similar in low- and high-income populations.
Kürüm, Esra, Lustig, Roger, Schuck-Paim, Cynthia, Shioda, Kayoko, Simonsen, Lone, Taylor, Robert J, Warren, Joshua L, Weinberger, Daniel M   +7 more
core   +2 more sources

Monitoring the introduction of pneumococcal conjugate vaccines into West Africa: design and implementation of a population-based surveillance system. [PDF]

, 2012
Routine use of pneumococcal conjugate vaccines (PCVs) in developing countries is expected to lead to a significant reduction in childhood deaths. However, PCVs have been associated with replacement disease with non-vaccine serotypes.
Adegbola, Richard A, Akinsola, Bolanle, Baldeh, Ignatius, Greenwood, Brian M, Hill, Philip C, Howie, Stephen RC, Ikumapayi, Usman N, Jasseh, Momodou, Knoll, Maria Deloria, Lee, Ellen, Levine, Orin S, Mackenzie, Grant A, Plumb, Ian D, Saha, Debasish, Sambou, Sana, Touray, Kebba, Uchendu, Uchendu, Usuf, Effua, Wattiaux, Andre   +18 more
core   +2 more sources

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults

Human Vaccines & Immunotherapeutics, 2012
HIV-patients have excess of pneumococcal infection. We immunized 40 HIV-patients twice with pneumococcal conjugate vaccine (Prevnar, Pfizer) +/− a TLR9 agonist (CPG 7909).
Rasmus Offersen, Jesper Melchjorsen, Søren R. Paludan, Lars Østergaard, Martin Tolstrup, Ole S. Søgaard   +5 more
doaj   +1 more source

Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England

PLoS ONE, 2018
Background In April 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the infant immunisation schedule in England and Wales. Despite limited serotype replacement in invasive pneumococcal disease (IPD) during the first four post ...
J. Southern, N. Andrews, P. Sandu, C. Sheppard, P. Waight, N. Fry, A. V. van Hoek, E. Miller   +7 more
semanticscholar   +1 more source

ERA OF CONJUGATE VACCINES: INTERNATIONAL EXPERIENCE OF SUCCESSFUL APPLICATION

Педиатрическая фармакология, 2008
The article highlights comparative characteristics of the polysaccharide and conjugate vaccines against pneumococcal infection, meningococcosis and haemophilus influenza. The author stresses the advantage of the conjugate vaccines.
M.V. Fedoseenko, M.G. Galitskaya, L.S. Namazova   +2 more
doaj   +2 more sources

Pneumococcal conjugate vaccine--a health priority.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008
Pneumonia is a major cause of childhood mortality and morbidity. Streptococcus pneumoniae is the most important bacterial pathogen causing pneumonia in children. The HIV epidemic has increased the burden and severity of childhood pneumococcal pneumonia and invasive disease fortyfold.
Zar, Heather J, Madhi, Shabir A
openaire   +5 more sources